Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Diranersen · ISIS 814907, BIIB-080

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by BIOGEN

Phase 2 Most advanced trial
BIIB Developer
1 Registered trials

What is Diranersen?

Diranersen (ISIS 814907, BIIB080) is an antisense oligonucleotide studied in mild cognitive impairment and Alzheimer's disease dementia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ISIS 814907, BIIB-080
Drug type
Oligonucleotide (Antisense oligonucleotide)
Mechanism
Gene silencing
Therapy area
Neurology
Developer
BIOGEN (BIIB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
96J3L33PWD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05399888 Phase 2 Mild Cognitive Impairment Due to Alzheimer's Disease Active not recruiting BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's Disease DementiaMild Cognitive Impairment Due to Alzheimer's Disease

More from BIOGEN

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind Diranersen

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.